Brian Walsh Email & Phone Number

Etobicoke, On, Ca

Etobicoke, On, Ca

Norwood, Massachusetts, Us

• Partner with R&D to define asset strategy for immuno-oncology pipeline• Led in-licensing of two pre-clinical assets • Responsible for commercial evaluation across all business development activities • Lead corporate communications and investor relations functions • 2022 Winner of the CORE Values Award for “Relentlessly Transforming Corbus”

Norwood, Massachusetts, Us

• Led global launch preparations for lenabasum ahead of pivotal data in three rare disease indications: Systemic Sclerosis, Dermatomyositis, and Cystic Fibrosis• Drove global launch plan development and the build-out of commercial capabilities • Developed and launched the multi-channel disease education campaign “Totality in Systemic Sclerosis” to raise awareness of the burden and unmet need of the disease

Boston, Massachusetts, Us

• Led marketing for the flagship Rebif® brand and preparations for the US Mavenclad® launch • Exceeded the Rebif® operating plan with >$1B Net Sales each year (~70% of company sales) • Grew Rebif® share in the interferon segment each year and achieved the #1 New to Therapy Interferon claim for the first time in brand history• Managed a team of ten marketing talents and an annual promotional investment >$30M • 2017 President’s Award winner for leadership of the US Mavenclad® launch preparations

Boston, Massachusetts, Us

• Responsible for the commercial success of a $200M portfolio of Fertility specialty injectable products, including brand positioning, messaging, tactics, and pricing • Led the Gonal-f® brand through a sales turnaround with two consecutive years of exceeding plan and grew market share in the category from 45% to 54% • Managed a marketing team of four and a six-member field-based Thought Leader Liaison team with responsibilities for key external KOL and advocacy group relationships• Launched the Gonal-f® Redi-ject, a new innovative drug delivery device

Boston, Massachusetts, Us

• Led franchise operations for a business unit generating ~$400M in Net Sales in the areas of Fertility, Growth Hormone Deficiency, and HIV• Restructured the national sales force to improve engagement, customer reach, and efficiency• 2013 President’s Award winner recognizing exceptional contribution to the business results

Boston, Massachusetts, Us

• Managed multiple aspects of the EGRIFTA® launch as a new class of treatment for an HIV-associated metabolic condition • Led the development of the EGRIFTA® consumer campaign that won silver for the Best Point-of-Care Campaign and bronze for the Best New Drug Launch at the DTC National Conference• Developed and implemented DTC programs in key regional markets for EGRIFTA® that included out-of-home, print, and events that drove a 20% increase in demand • Named as a 2012 ‘Top 25’ DTC Marketer of the Year by the DTC National Conference

Boston, Massachusetts, Us

• Led multiple US commercial evaluations for in-licensing opportunities and business cases to expand indications on existing assets • Developed the US Commercialization Plan for pipeline assets in Lupus (SLE & LN)

• Primary day-to-day engagement leader of project teams working with Top 10 Global Pharmaceutical clients to increase top-line growth for new and existing brands • Responsible for building relationships across a client organization to gather input and cultivate buy-in of project recommendations• Regularly led the design, execution, and analysis of extensive primary qualitative and quantitative market research Engagements included: o Product launch readiness support for a first-in-class metastatic breast cancer treatment o Launch strategy development for the Psoriasis indication of an anti-TNF inhibitoro Franchise growth opportunity assessment for a Renal Care franchise o Franchise portfolio strategy and co-positioning for a company with three Type-II Diabetes pipeline assets o New adult indication launch strategy for an established ADHD brand o Patient advocacy group engagement strategy for the HIV and Hepatitis communities

Oxford, Oxfordshire, Gb

Raritan, New Jersey, Us

• Sold Aciphex®, Reminyl®, Risperdal® and Sporanox® products • Achieved 182% of sales forecast for 2003, ranked 1st in District, 2nd of 24 in Region • Selected for Janssen Sales Management Development Program

New Brunswick, Nj, Us

• Supervised operations and planning for Tylenol® and Motrin® products• Managed 23 full-time direct reports

Mba, Business

Bs, Chemistry